ClinicalTrials.gg
TerminatedNCT04774809Updated Jul 13, 2022

Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo

A Phase 2/3 interventional study of Low Dose SHR0302 Ointment BID and High Dose SHR0302 Ointment BID in Vitiligo, sponsored by Reistone Biopharma Company Limited. Terminated at 16 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-07-13.

Sponsored by Reistone Biopharma Company Limited (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Why this study was terminated
terminated by sponsor

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jan 2020, registered Feb 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Vitiligo with a site in China — 24 open to participants now, 29 under way, 8 of them phase 3. Vitiligo · China.

Enrollment
22nd of 32
75 · median 150
Started
2020
with 1 other
Phase 2/3
3 of 39
2 open now
Registered
5th of 39
by date

Among the 39 studies in Vitiligo with a site in China, this one is the 22nd largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 2/3, and was the 5th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

24 of the 39 studies in Vitiligo with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Vitiligo with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of SHR0302 ointment in adult patients with Vitiligo.

Read the detailed description

This study is a phase II/Ⅲ seamless adaptive clinical trial to evaluate the efficacy and safety of SHR0302 ointment in adult patients with non-segmental vitiligo.

03

Conditions studied

  • Vitiligo

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who voluntarily signed an form.
  2. Ages at ≥18 and ≤ 65 years
  3. Clinical diagnosis of non-segmental vitiligo.
  4. All women and men who are likely to give birth must be willing to use at least one efficient method of from the signing of the informed consent form to 1 month after the last dose of IP.
  5. Subjects who agree to discontinue all vitiligo-related treatments and camouflage cosmetics with therapeutic effect between screening visit and the last follow-up visit.
  6. Subjects who are willing and able to comply with the scheduled visits and treatment plan, laboratory testing and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who were diagnosed with segmental vitiligo, mixed vitiligo or unclassified vitiligo.
  2. Subjects with historical or current evidence of disease or lab test abnormalities or with disease that require the administration of prohibited drugs in this study.
  3. Subjects with a malignant tumor or a history of malignant tumor (except for fully treated or resected skin non- basal cell carcinoma or squamous cell carcinoma).
  4. Pregnant or lactating female subjects;
  5. Subjects who have previously received JAK inhibitors therapy, systemic or oral
  6. Subjects who had used any biologics within12 weeks before the baseline or 5 half-lives (whichever is longer).
  7. Subjects who participated in other interventional clinical studies within 4 weeks before the baseline visit, or who were still within 5 half-lives of the last dose of the intervention clinical study drug at baseline.
  8. Subjects who received a live or within 8 weeks before the baseline visit.
  9. Any other condition that causes the subject to be unfit for the study as per discretion of the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Active comparator
    SHR0302 Low Dose

    Drug: SHR0302 SHR0302 Ointment BID Low Dose

    Drug: Low Dose SHR0302 Ointment BID

  • Active comparator
    SHR0302 High Dose

    Drug: SHR0302 SHR0302 Ointment BID High Dose

    Drug: High Dose SHR0302 Ointment BID

  • Placebo comparator
    Placebo Comparator: Vehicle

    Drug: vehicle Vehicle BID Placebo

    Other: Placebo Comparator: Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 2

    Phase 2: Percentage of change in face and neck vitiligo area scoring index (F-VASI) compared with baseline at week 24.

    Time frame: 24 weeks

  2. Phase 3

    Phase 3: Percentage of subjects whose face and neck vitiligo area scoring index improved by at least 75% (F-VASI75) compared with the baseline at week 24.

    Time frame: 24 weeks

07

Study locations

16 sites
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • Wuhan No.1 Hospital
    Wuhan, Hubei, China
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning, China
  • Xijing Hospital, Air Force Medical University
    Xi'an, Shaanxi, China
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai 200071, China
  • West China School of Medicine
    Chengdu, Sichuan, China
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, Tianjin 300120, China
  • Hangzhou Third Hospital
    Hangzhou, Zhejiang, China
  • Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Ningbo No.2 Hospital
    Ningbo, Zhejiang, China
  • The First Hospital of Jillin University
    Changchun, 130021, China
  • Sun. Yai- Sen Memorial Hospital, Sun. Yai- Sen University
    Guangzhou, 51000, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, 310014, China
  • Jiangsu Province Hospital
    Nanjing, 210006, China
  • Huashan Hospital Affiliated To Fudan University
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Mar 2022, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2021
First posted
Mar 1, 2021
StartActual
Jan 29, 2020
Primary completionActual
Mar 21, 2022
CompletionActual
Mar 21, 2022
Last update
Jul 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04774809
Responsible party
Sponsor
First posted
Mar 1, 2021
Start date
Jan 29, 2020
Primary completion
Mar 21, 2022
Completion
Mar 21, 2022
Last update
Jul 13, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivarmacitinib

Start the discussion